Furthermore, we also identified 14 patients (33%) who harbored ROS1 point mutations, of which ROS1 G2032R, the most common mechanism of crizotinib resistance in ROS1‐positive NSCLC, was present in 11 patients (Fig. 2C). The gene discussed is ROS1; the disease is non-small cell lung carcinoma.